PBM (Psyence Biomedical) Debt-to-Equity : -0.75 (As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Debt-to-Equity?

Psyence Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.73 Mil. Psyence Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Psyence Biomedical's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-0.98 Mil. Psyence Biomedical's debt to equity for the quarter that ended in Sep. 2023 was -0.75.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Psyence Biomedical's Debt-to-Equity or its related term are showing as below:

PBM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.95 Med: -0.95 Max: -0.95
Current: -0.95

During the past 4 years, the highest Debt-to-Equity Ratio of Psyence Biomedical was -0.95. The lowest was -0.95. And the median was -0.95.

PBM's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs PBM: -0.95

Psyence Biomedical Debt-to-Equity Historical Data

The historical data trend for Psyence Biomedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Debt-to-Equity Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

-0.95

Psyence Biomedical Semi-Annual Data
	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-Equity	-	N/A	-	-0.75	-0.95

Competitive Comparison of Psyence Biomedical's Debt-to-Equity

For the Biotechnology subindustry, Psyence Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Debt-to-Equity falls into.

Psyence Biomedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Psyence Biomedical's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.448	+	0)	/	-10.973
	=	-0.95

Psyence Biomedical's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.733	+	0)	/	-0.977
	=	-0.75

Psyence Biomedical (NAS:PBM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Psyence Biomedical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.